SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT00028366

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Randomized, Comparative Study of Lopinavir/Ritonavir Versus GW433908 and Ritonavir Versus Lopinavir/Ritonavir and GW433908 (In Combination With Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase Inhibitors) in HIV-1-Infected Subjects With Virologic Treatment Failure

Ritonavir (RTV) is a protease inhibitor (PI) commonly used to increase drug levels of other PIs in HIV drug treatment. The purpose of this study is to compare a combination of drugs which includes RTV and 2 protease inhibitors (PIs) with 2 combinations that include RTV and another PI. This study also will compare the effectiveness, safety, tolerability, and drug levels in the blood of these anti-HIV drug combinations.

NCT00028366 HIV Infections
MeSH:HIV Infections

4 Interventions

Name: Fosamprenavir

Type: Drug

Name: Lopinavir/Ritonavir

Type: Drug

Name: Ritonavir

Type: Drug

Name: Tenofovir disoproxil fumarate

Type: Drug

Purpose: Treatment

Parallel Assignment

There is one SNP


1 A5147S

Note: Accrual into A5143 and A5147S has been discontinued. --- A5147S ---

- Midazolam within 7 days of study entry - Allergic or sensitive to study drugs - Excessive drug or alcohol use - Serious illness requiring treatment and/or hospitalization and have not completed therapy, or are not stable on therapy for at least 14 days prior to study entry - Pregnant or breastfeeding Note: Accrual into A5143 and A5147S has been discontinued. --- A5147S ---

In substudy A5147S, intensive 12-hour pharmacokinetic sampling for APV, LPV, and RTV will be conducted. --- A5147S ---

HPO Nodes